A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

被引:678
|
作者
Sargent, DJ
Goldberg, RM
Jacobson, SD
Macdonald, JS
Labianca, R
Haller, DG
Shepherd, LE
Seitz, JF
Francini, G
机构
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[2] St Vincent Comprehens Canc Ctr, New York, NY USA
[3] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[4] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA
[5] Queens Univ, Natl Canc Inst Canada, Kingston, ON, Canada
[6] Univ Mediterranean, Marseille, France
[7] Univ Siena, I-53100 Siena, Italy
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2001年 / 345卷 / 15期
关键词
D O I
10.1056/NEJMoa010957
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Adjuvant chemotherapy is standard treatment for patients with resected colon cancer who are at high risk for recurrence, but the efficacy and toxicity of such treatment in patients more than 70 years of age are controversial. Methods: We performed a pooled analysis, based on the intention to treat, of individual patient data from seven phase 3 randomized trials (involving 3351 patients) in which the effects of postoperative fluorouracil plus leucovorin (five trials) or fluorouracil plus levamisole (two trials) were compared with the effects of surgery alone in patients with stage II or III colon cancer. The patients were grouped into four age categories of equal size, and analyses were repeated with 10-year age ranges (less than or equal to 50, 51 to 60, 61 to 70, and >70 years), with the same conclusions. The toxic effects measured in all trials were nausea or vomiting, diarrhea, stomatitis, and leukopenia. Patients in the fluorouracil-plus-leucovorin and fluorouracil-plus-levamisole groups were combined for the efficacy analysis but kept separate for toxicity analyses. Results: Adjuvant treatment had a significant positive effect on both overall survival and time to tumor recurrence (P<0.001 for each, with hazard ratios of death and recurrence of 0.76 [95 percent confidence interval, 0.68 to 0.85] and 0.68 [95 percent confidence interval, 0.60 to 0.76], respectively). The five-year overall survival was 71 percent for those who received adjuvant therapy, as compared with 64 percent for those untreated. No significant interaction was observed between age and the efficacy of treatment. The incidence of toxic effects was not increased among the elderly (age >70 years), except for leukopenia in one study. Conclusions: Selected elderly patients with colon cancer can receive the same benefit from fluorouracil-based adjuvant therapy as their younger counterparts, without a significant increase in toxic effects. (N Engl J Med 2001;345:1091-7.) Copyright (C) Massachusetts Medical Society.
引用
收藏
页码:1091 / 1097
页数:7
相关论文
共 50 条
  • [21] Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
    Chen, Xin
    Tu, Junhao
    Xu, Xiaolan
    Gu, Wen
    Qin, Lei
    Qian, Haixin
    Jia, Zhenyu
    Ma, Chuntao
    Xu, Yinkai
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [22] Competing nomograms help in the selection of elderly patients with colon cancer for adjuvant chemotherapy
    Dan Li
    Chenhan Zhong
    Xiujun Tang
    Linzhen Yu
    Kefeng Ding
    Ying Yuan
    [J]. Journal of Cancer Research and Clinical Oncology, 2018, 144 : 909 - 923
  • [23] Adjuvant chemotherapy in elderly patients (&gt;75 years) completely resected for colon cancer stage III compared to younger patients; toxicity and prognosis
    Jensen, Soren A.
    Vilmar, Adam
    Sorensen, Jens B.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 94 - 94
  • [24] Survival benefit of adjuvant chemotherapy in elderly patients with colon cancer: a systematic review and meta-analysis
    Nobuaki Hoshino
    Ryuhei Aoyama
    Koya Hida
    [J]. International Journal of Clinical Oncology, 2021, 26 : 883 - 892
  • [25] Survival benefit of adjuvant chemotherapy in elderly patients with colon cancer: a systematic review and meta-analysis
    Hoshino, Nobuaki
    Aoyama, Ryuhei
    Hida, Koya
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (05) : 883 - 892
  • [26] Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis
    Ejaz, Aslam
    Casadaban, Leigh
    Maker, Ajay V.
    [J]. JOURNAL OF SURGICAL RESEARCH, 2017, 215 : 12 - 20
  • [27] Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (≥75 years) Patients
    Mattiucci, Gian-Carlo
    Falconi, Massimo
    Van Stiphout, Ruud G. P. M.
    Alfieri, Sergio
    Calvo, Felipe A.
    Herman, Joseph M.
    Maidment, Bert W., III
    Miller, Robert C.
    Regine, William F.
    Reni, Michele
    Sharma, Navesh
    Partelli, Stefano
    Genovesi, Domenico
    Balducci, Mario
    Deodato, Francesco
    Valentini, Vincenzo
    Morganti, Alessio G.
    [J]. ANTICANCER RESEARCH, 2015, 35 (06) : 3441 - 3446
  • [28] Duration of adjuvant chemotherapy for colon cancer and survival among the elderly
    Neugut, Alfred I.
    Matasar, Matthew
    Wang, Xiaoyan
    McBride, Russell
    Jacobson, Judith S.
    Tsai, Wei-Yann
    Grann, Victor R.
    Hershman, Dawn L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2368 - 2375
  • [29] Age Determines Adjuvant Chemotherapy Use in Resected Stage II Colon Cancer
    Hagerty, Brendan L.
    Aversa, John G.
    Dominguez, Dana A.
    Davis, Jeremy L.
    Hernandez, Jonathan M.
    McCormick, James T.
    Blakely, Andrew M.
    [J]. DISEASES OF THE COLON & RECTUM, 2022, 65 (10) : 1206 - 1214
  • [30] Tailored-dose capecitabine chemotherapy as adjuvant treatment in elderly colon cancer patients
    Chang, Hye Jung
    Lee, Keun-Wook
    Choi, In Sil
    Kim, Yu Jung
    Kim, Jee Hyun
    Bang, Soo-Mee
    Lee, Jong-Seok
    [J]. CANCER RESEARCH, 2010, 70